Next-generation influenza vaccines: opportunities and challenges

Chih-Jen Wei1, Michelle C. Crank2, John Shiver3, Barney S. Graham2, John R. Mascola2 and Gary J. Nabel5

Abstract | Seasonal influenza vaccines lack efficacy against drifted or pandemic influenza strains. Developing improved vaccines that elicit broader immunity remains a public health priority. Immune responses to current vaccines focus on the haemagglutinin head domain, whereas next-generation vaccines target less variable virus structures, including the haemagglutinin stem. Strategies employed to improve vaccine efficacy involve using structure-based design and nanoparticle display to optimize the antigenicity and immunogenicity of target antigens; increasing the antigen dose; using novel adjuvants; stimulating cellular immunity; and targeting other viral proteins, including neuraminidase, matrix protein 2 or nucleoprotein. Improved understanding of influenza antigen structure and immunobiology is advancing novel vaccine candidates into human trials.

Vaccination represents an efficient and cost-effective way to contain influenza epidemics and preserve public health. Since their introduction in the 1940s, seasonal influenza vaccines have saved countless lives and limited pandemic spread. Influenza viruses nonetheless continue to evolve through genetic mutation and escape from natural immunity, and vaccines must be updated yearly. The protective efficacy of the current licensed vaccines varies each year (Fig. 1a), depending on the antigenic match between circulating viruses and vaccine strains. The immune status of the host can also affect vaccine efficacy. For example, young and elderly individuals are more susceptible to the complications of influenza infection1–3.

New influenza viruses have precipitated pandemics several times over the past 100 years, specifically in 1918, 1957, 1968 and 2009 (Ref. 4). The threat of the re-emergence of old pandemic viruses and the emergence of novel viruses with pandemic potential underscore the need for durable and broadly protective influenza vaccines. Advances in immunology and virology, together with information from structural biology and bioinformatics, are facilitating the development of novel vaccine approaches4–6. Of particular interest are human broadly neutralizing antibodies directed to conserved viral structures. These antibodies arise naturally and can also be elicited through immunization7–16.

Current licensed influenza vaccines contain either inactivated or live attenuated influenza viruses. Most inactivated vaccines consist of split viruses or subunit influenza antigens (Table 1). Split vaccines are produced by disrupting viral particles with chemicals or detergents and are widely used because of the ease of manufacture. Subunit vaccines contain viral haemagglutinin (HA) and neuraminidase (NA) proteins that are partially purified after chemical or detergent splitting17. The live-attenuated influenza vaccines are made from cold-adapted viruses that do not replicate well at body temperature and are administered intranasally. This type of vaccine induces strong local mucosal immunity but is only recommended for non-pregnant individuals between 2 and 49 years of age18. The HA content in the licensed vaccines must be determined and standardized, but the quantity and quality of NA can vary by vaccine and by manufacturing processes. The trivalent vaccine has viral components from two influenza A strains and one influenza B strain, whereas the quadrivalent vaccine formulations add an additional influenza B virus. The viruses chosen for the vaccines are typically grown in chicken eggs; therefore the production heavily relies on a steady egg supply. Any modifications to viral protein formulations add an additional influenza B virus. The viruses chosen for the vaccines are typically grown in chicken eggs; therefore the production heavily relies on a steady egg supply. Any modifications to viral protein formulation must not impair influenza replication, which limits the repertoire of modified proteins that can be incorporated into a vaccine. Newer technology that utilizes cell culture for growing viruses has been developed, but the selected vaccine strains still need to be adapted for growth on cells, and the manufacturing cost remains high. More recently, a recombinant HA-based subunit vaccine produced from insect cells showed efficacy in healthy adults and improved protection in older subjects19.

Innovative approaches to vaccine design have been explored to develop a ‘universal’ influenza vaccine. The goal is to induce cross-protective immunity against diverse influenza viruses and prolong the duration of
**A spectrum of efficacy for influenza vaccines.**

**a** | Effectiveness of seasonal influenza vaccines from 2009 to 2019 (Data from ‘CDC: Past Seasons Vaccine Effectiveness Estimates’). The vaccine effectiveness is estimated from the US Flu Vaccine Effectiveness Network and measures the flu vaccine’s effectiveness in preventing outpatient medical visits due to laboratory-confirmed influenza. Adjusted overall vaccine effectiveness (%) and 95% confidence interval are shown.

**b** | Phylogenetic tree of influenza A and influenza B haemagglutinin (HA). Eighteen influenza A HA subtypes have been detected in nature, and they can be further divided into group 1 and group 2 based on amino acid sequence composition, whereas influenza B HA subtypes have differentiated into two serologically distinct lineages (B/Victoria/2/87-like and B/Yamagata/16/88-like). Current licensed flu vaccines consist of one H1 strain, one H3 strain and one or two influenza B viruses. H2 virus also has the ability to infect humans and caused the pandemic in 1957. Occasionally, transmission of zoonotic influenza viruses, such as H5, H7 and H9, to humans has been reported. *H17 and H18 are from bat influenza. The scale bar indicates the numbers of amino acid substitutions per site.

**c** | Incremental steps towards a ‘true’ universal influenza vaccine. Vaccine breadth against divergence of influenza strains, ranging from strain-specific (effective against a single, matched strain) to subtype-specific (effective against all or most strains within a given subtype), multi-subtype (effective against select subtype viruses), pan-group/lineage (effective against most subtype viruses within a group/lineage), type A (against all type A viruses), types A and B (against all type A and B viruses) and universal coverage (against most seasonal, drifted and pandemic strains for multiple years in a single product). Part c adapted from Erbelding et al.4.
the immune responses. Among the universal influenza vaccine platforms are innovative technologies that utilize nucleic acid-based delivery, alternate viral vectors, recombinant proteins and virus-like particles (Table 2). In addition to the conserved epitopes on HA, other viral structures, such as NA and the extracellular domain of matrix protein 2 (M2), are also being considered. Internal viral proteins, such as nucleoprotein (NP) and matrix protein 1 (M1), have also been targeted for the induction of cross-reactive T cell responses.

In this Review, we summarize the major advances in the field of influenza vaccines that are guiding the development of next-generation influenza vaccines. The major targets of current seasonal vaccines as well as vaccines in the development pipeline are reviewed, with a focus on improvements harnessing new insights from influenza antigen structure and human immunity. We highlight some of the unique challenges facing the influenza vaccine research field, many of which have contributed to the maintenance of established technologies, production systems and methods developed decades ago and which will require collaboration among the wide range of stakeholders, from funding sources to basic scientists, regulators and vaccine manufacturers.

Expanding the breadth of current vaccines
Influenza A viruses can be antigenically divided based on two key viral surface glycoproteins, HA and NA, whereas influenza B viruses form a single antigenic group with two distinct lineages, the B/Victoria/2/87-like and B/Yamagata/16/88-like lineages (Fig. 1b). There are 18 different HA subtypes that can be classified into two major phylogenetic groups based on genetic sequence (Fig. 1c).

Current licensed influenza vaccines contain three (trivalent inactivated vaccine) or four (quadrivalent inactivated vaccine) virus strains responsible for seasonal epidemics and need to be reformulated annually for the Northern and Southern Hemispheres based on global surveillance of drift in the circulating strains. Traditionally, the haemagglutination inhibition (HAI) antibody titre induced by the seasonal vaccines is used as an immune correlate of protection from influenza virus infection, but it tends to work only for homologous virus strains. The HAI titre correlates with in vitro neutralization of matched-strain influenza viruses, and early work using this assay demonstrated a serum titre of 1:18–1:36 correlated with 50% protection from infection in humans. Seasonal influenza vaccines are predominantly produced by propagation of influenza virus in chicken eggs, followed by inactivation, which is a time-consuming and labour-intensive process (see Table 1 for further details). Adaptation to infection in eggs has been noted to result in occasional mutations in HA that may impact the immune response.

### Table 1 | Current licensed vaccines in the United States and Europe

| Region          | Vaccine technology/ platform | Vaccine type | Vaccine name (manufacturer) | Target/ MOA | Adjuvant used |
|-----------------|-----------------------------|-------------|-----------------------------|-------------|---------------|
| United States   | Inactivated virus           | Split virus | Afluria (Seqirus)            | HAI         | None          |
|                 |                             |             | Fluarix (GSK)                | HAI         | None          |
|                 |                             |             | FluLavel (GSK)               | HAI         | None          |
|                 |                             |             | Fluzone, Fluzone HD (Sanofi Pasteur) | HAI | None          |
|                 |                             |             | Fluad (Seqirus)              | HAI         | None          |
|                 | Subunit                     | Fluvin (CLS Limited) | HAI             | None         |
|                 |                             |             | Flucelvax (Novartis)         | HAI         | None          |
|                 | Live-attenuated             | Live, cold-adapted | FluMist (AstraZeneca)      | HAI         | None          |
|                 | Recombinant protein         | Non-purified HA | FluBloc (Sanofi Pasteur)  | HAI         | None          |
| Europe          | Inactivated virus           | Split virus | Influvac, Imuvac (Abbott)    | HAI         | None          |
|                 |                             |             | Fluarix, Alpharix, Influsplit (GSK) | HAI | None          |
|                 |                             |             | 3Fluart (Omninvent)          | HAI         | Alum          |
|                 |                             |             | Afluria, Enzira (Pfizer/CSL) | HAI         | None          |
|                 |                             |             | Vaxigrip, Vaxigrip Tetra    | HAI         | None          |
|                 | Subunit                     | Agrippal (Seqirus) | HAI    | None         |
|                 |                             |             | Fluad (Seqirus)              | HAI         | MF59          |
|                 | Live-attenuated             | Live, cold-adapted | Fluenz Tetra (AstraZeneca) | HAI         | None          |

HA, haemagglutinin; HAI, haemagglutination inhibition; HD, high-dose; MOA, mode of action. Sources: European Centre for Disease Prevention and Control: seasonal influenza vaccines, CDC: United States influenza vaccines 2019–2020.
**Table 2 | Vaccine platforms in clinical development**

| Vaccine technology/platform | Vaccine type | Sponsor | Target/MAO | Development stage | Clinical trial ID | Refs |
|-----------------------------|--------------|---------|------------|------------------|-----------------|------|
| Nucleic acid DNA            | HA NAbs      | Vaccine Research Center, NIAID, NIH | Phase I | NCT00776211; NCT00408109; NCT00499331; NCT01086657; NCT00738395; NCT01498718; NCT00886111; NCT0095982; NCT02206464 | 61,230–234 |
| mRNA                       | Moderna      | HA NAbs | Phase I    | NCT03345043      |                 | 275,276 |
| Vector                     | Alphavirus–HA | HA NAbs | Phase I, II| NCT00440362; NCT00706732 |                 | 275,273–276 |
| Adenovirus–HA              | HA NAbs      | NIAID, NIH; PaxVax; VaxArt; Vaxin/Alimmune | Phase I, II | NCT01688297; NCT01006798; NCT01443936; NHRC31230; NHRC3100002; NCTD1335347 | 275,273–276 |
| Chimpanzee adenovirus–NP + M2 | Jerren Institute | T cells | Phase I | NCT01623518; NCT01813862 | 275,271 |
| Modified vaccinia virus Ankara–HA; NP + M1 | Erasmus Medical Center; Jenner Institute; Vaccitech | HA NAbs; T cells | Phase I, II | NTR3401; NCT00942071; NCT01818362 | 66,275,276, 273–274 |
| Recombinant protein; VLP   | Ferritin-based nanoparticle–HA; HA stem | Vaccine Research Center, NIAID, NIH | HA NAbs | Phase I | NCT03186781 | 66,275 |
| VLP–HA; NA; M1; M2          | Novavax      | HA NAbs; T cells | Phase I, II | NCT01897701 | 62 |
| Peptide–HA, NP, M1          | BiondVax     | T cells; B cells | Phase II (USA); Phase III (EU) | NCT02691130; NCT02293317; NCT03450915; NCT01146119; NCT00877448 | 61,81,24 |
| Peptide–NP; M1; M2          | SEEK         | T cells | Phase IIb  | NCT02962908      | 85 |
| Live virus                  | M2-deficient single replication virus | FluGen | B cells | Phase II      | NCT03999554 | 84,27 |

HA, haemagglutinin; NIH, National Institutes of Health; M1, matrix protein 1; M2, matrix protein 2; MOA, mode of action; NA, neuraminidase; NAbs, neutralizing antibody; NIAID, National Institute of Allergy and Infectious Disease; NP, nucleoprotein; VLP, virus-like particle; US Department of Defense Protocol. Dutch Trial Register.

**Antigen dose, regimen and optimization.** Even though the development of a ‘true’ universal influenza vaccine remains a challenging goal, strategic plans have been proposed by field experts and government agencies. Many steps have been taken towards improving current seasonal vaccines by expanding the breadth of protection within a subtype or across a group. They have shown progressive but incremental degrees of efficacy (Fig. 1c). For example, a high-dose, quadrivalent, inactivated vaccine is more effective than a standard dose vaccine at reducing the clinical outcomes associated with influenza infection and is now recommended vaccine at reducing the clinical outcomes associated with influenza infection and is now recommended.

Vaccination with a DNA prime followed by seasonal vaccine boost not only improved HA antibody responses but also induced protective immunity against divergent H1N1 and H5N1 in mouse and ferret challenge models. This prime-boost immunization strategy has shown similar immunogenicity in clinical trials, and together with a H2N2 vaccine can constitute the first generation of a ‘pan-group 1 HA’ pre-pandemic vaccine.
antigens, such as synthetic polypeptides. New classes of immunoogens that target the common viral structures among all HA antigens have also been designed and evaluated, and antibodies that react broadly with all HA antigens within group 1, group 2 or influenza B have been isolated, further paving a pathway to a vaccine to cover most influenza A and influenza B strains. A true universal vaccine, however, should protect against all influenza strains and should be durable for multiple years in a single product.

**Delivery and display.** Advances in delivery methods, including live-attenuated vaccines, viral vectors, mRNA technology and nanotechnology, have shown promise in inducing more cross-reactive immunity. A prototypical recombinant influenza B virus vaccine that incorporated mutations in viral PB1 and PB2 genes resulted in a stable, attenuated virus that conferred protection against lethal heterologous influenza B virus challenge. Replication-defective vectors, such as MVA, adenovirus, Newcastle disease virus and alphasivirus, can express various influenza antigens and can be used in a prime-boost regimen, where they have shown some degree of success in eliciting both homologous and heterologous immunity.

A nucleoside-modified mRNA vaccine encoding HA from the 2009 pandemic H1N1 virus formulated with lipid nanoparticles induced HA stem-directed antibodies in rabbits and mice and protected mice from a heterosubtypic virus challenge. Virus-like particle influenza vaccines have also been evaluated in various clinical trials, and some have elicited long-lasting immunity and induced cross-reactive HAI responses against heterologous strains. Recombinant protein-based vaccines consist of peptides from conserved viral structural genes resulting in a stable, modified live influenza viruses are also being evaluated in late-stage clinical trials. Influenza virus HA has also been rationally designed for presentation on a bacterial-based ferritin nanoparticle. These particles allow HA to retain its native trimeric conformation while displayed in an ordered array, to increase valency that may facilitate cross-linking of B cell receptors. In animal models, this nanoparticle vaccine improved HA antibody responses and conferred protection against heterologous virus challenge, and it is currently being evaluated in a phase I clinical trial.

**Novel HA-based vaccines**

Antibodies against HA are a major component of the human immune response to both natural influenza virus infection and influenza vaccination, and measurement of antibody responses against HA by the HAI assay is the recognized correlate of protection from influenza virus infection. As a result, HA is a target for both current seasonal vaccines and many candidates in development for universal influenza vaccines. Seasonal vaccine manufacturers characterize their vaccine products, in part, by measuring and standardizing the quantity of each HA component of their vaccines. Recent advances in structural biology, including crystallography, electron microscopy and bioinformatics, have enabled a deeper and more nuanced understanding of the structure of HA, which has subsequently provided opportunity for vaccinologists to employ structure-guided vaccine design.

HA is a type I membrane glycoprotein that forms a homotrimer that is typically glycosylated at between five and seven sites per monomer, and is the major target of neutralizing antibodies. HA mediates viral entry by binding to its receptor, terminal sialic acids on glycoproteins or glycolipids of host respiratory epithelial cells, and mediates fusion of the viral envelope with the host cell in the endosome. The molecular structures of HA from different subtypes have been determined. The overall architecture of HA from different strains is conserved, although the surface sequence composition and glycosylation patterns differ among influenza virus subtypes and types, especially in regions near or at the receptor binding site. The RBS itself is a shallow pocket surrounded by three secondary elements, the 130-loop, the 190-helix and 220-loop, with a base consisting of four highly conserved amino acid residues. In both H1 and H3 viruses, the number of N-linked glycosylation sites, such as synthetic polypeptides, and modified live influenza viruses have also been evaluated in various seasonal vaccination studies. These antibodies provide immunity by blocking viral entry to host cells or preventing receptor-mediated endocytosis. Memory B cells and long-lived plasma cells are often found following infection or immunization to provide durable protection against matched or closely-related viruses. However, these antibodies tend to be strain-specific and do not neutralize drifted variants mainly due to the high mutation rate of the HA globular head, especially in regions around the RBS.

Broadly neutralizing antibodies against the more conserved stem region of HA were identified as early as the 1990s. The C179 monoclonal antibody, isolated in mice, displayed unusually broad specificity and neutralized many group 1 HA viruses, including H1, H2, H5, H6 and H9 subtypes. Unlike most HA antibodies that recognize the highly variable HA head region, C179 binds to a conserved stem region of the HA. A follow-up study has also shown that heterosubtypic protective immunity can be induced by vaccination with an immunogen lacking the head domain, suggesting that an HA stem-only immunogen could induce antibodies with more breadth. Subsequently, this class of antibodies was isolated from humans, and structures of several have been extensively characterized. Broadly neutralizing antibodies, such as CR6261 and F10, cross-react with most group 1 influenza A HA subtype viruses. Crystal structures of CR6261 and F10 in complex with HA revealed that both antibodies bind to a hydrophobic pocket on the stem near the fusion peptide with a very hydrophobic complementary domain region (CDR) H2.
and use a conserved tyrosine residue in CDR H3 to stabilize the interaction with HA. They inhibit the virus by fixing HA in its prefusion form, thereby inhibiting membrane fusion. Other stem-directed antibodies may inhibit proteolytic cleavage of HA, prevent viral replication by disrupting particle egress or inhibit NA enzymatic activity through steric hindrance.

Many of these stem-directed human antibodies were derived from the V\(_{H}\)1-69 germline, but antibodies that utilize different germline families, such as V\(_{H}\)1-18, V\(_{H}\)6-1 and V\(_{H}\)3-23, and additional neutralizing epitopes on the stem have also been identified. Most stem-directed antibodies neutralize influenza strains within group 1 or group 2, but a few have been shown to neutralize across both groups within influenza A and at least one, CR9114, protects mice from both influenza A and influenza B virus challenge, although it binds but does not neutralize influenza B in vitro. The generation of these broadly neutralizing antibodies by different vaccination platforms or immunogens in various animal models and in clinical trials has been demonstrated.

Although these stem-directed antibodies are present in humans, most appear to be less prevalent in human sera and less potent neutralizers than those directed to the HA head region. Several different approaches have been taken to overcome these challenges. Immunization of human subjects with pre-existing immunity to H1N1 and H3N2 viruses with pandemic vaccines that contain divergent head but conserved stem domains, such as H5N1 or H7N1, have been shown to induce stem-binding antibodies with limited neutralizing activity. Priming with a novel pandemic H5N1 or H7N9 DNA vaccine followed by matched-strain monovalent inactivated virus vaccine boost has improved the breadth of immune response in animals and in clinical trials over monovalent inactivated virus vaccine alone. Broadly neutralizing antibodies that neutralize both group 1 and group 2 influenza virus have indeed been isolated from vaccinees who received this regimen. Another approach is sequential immunization with synthetic, chimeric HA in which the HA1 domain is derived from different, novel subtypes while the stem remains the same. Prime/boost immunization with chimeric HA generates cross-neutralizing antibodies and protects animals from heterologous viral challenge. These chimeric HA vaccines have been evaluated in a phase I clinical trial, and the interim analysis suggested that stem binding antibodies that react with select group 1 HA subtypes (H1, H2, H9 and H18), measured by enzyme-linked immunosorbent assay, can be boosted in subjects with pre-existing anti-stem antibody titers, although neutralization was not evaluated. Additionally, chimeric HA vaccines can also be constructed with exotic head domain sequences from avian species, allowing the potential for sequential immunization and repeated boosting of cross-reactive, stem-directed antibodies. More recently, two groups independently designed and engineered a ‘headless’ HA construct in which only the NH\(_2\)-terminal and COOH-terminal regions of HA1 and entire HA2 were presented (Fig. 2b). In one design, the HA stem was stabilized by a trimerization domain, and in the
other, the stem was fused and presented on a bacterial ferritin nanoparticle\textsuperscript{18,115}. Both headless immunogens elicit heterosubtypic immunity and protect animals from a heterologous lethal H5N1 virus challenge. One is currently under evaluation in a phase I clinical trial\textsuperscript{122} (\textit{TABLE 2}). Overall, these stem-based immunogens represent promising candidates for broadly protective vaccines and warrant further clinical investigation.

In addition to the conserved stem epitopes, there are also new developments on broadly neutralizing antibodies targeting the HA head, especially the RBS. An antibody that binds close to antigenic site B, C139/1, was first reported in 2009, and it neutralizes many influenza subtypes (H1, H2, H3, H5, H9 and H13)\textsuperscript{99}. Many head-directed antibodies with varying degrees of specificity have subsequently been identified, and the majority of these antibodies tend to be subtype-specific\textsuperscript{10,11,13,15,16–18,20,96,97}. They neutralize the virus by blocking viral attachment to the host cells and, in general, utilize the CDR loop to make minimum contact with the relatively small RBS. Antibodies directed against additional sites in the HA head located outside the RBS have recently been identified that do not mediate HAI but can mediate neutralization\textsuperscript{122–124}. Antibodies to conserved epitopes on the interface of the HA head trimer recognize a broad spectrum of influenza viruses and confer hetero-subtypic protection in mice dependent on Fc activity\textsuperscript{125,126}. The challenge for vaccine design will be to present the minimum, most conserved residues in this binding pocket in a functional conformation, while avoiding the highly variable surrounding regions.

\textbf{Vaccines based on other viral proteins}

In addition to harnessing and improving the humoral immune response to the HA antigen, universal influenza virus vaccines could potentially benefit from incorporating diverse and more highly-conserved antigens.

\textbf{Neuraminidase}. A recent study utilizing a human influenza challenge model suggested that serum neuraminidase inhibition activity may be more predictive of susceptibility to live virus challenge than the current standard predictor of protection, the HAI titre\textsuperscript{127–129}. NA is a type II transmembrane glycoprotein composed of 11 subtypes that fall into three genetic groups (\textit{FIG. 3a}). This tetrameric protein removes terminal sialic acids and facilitates the release of newly formed viral particles\textsuperscript{130}. Although antibodies to NA have been identified\textsuperscript{131–134}, little is known about how they affect the outcome of influenza virus infection\textsuperscript{135}. NA is a validated drug target as small-molecule inhibitors to NA, such as oseltamivir, zanamivir and laninamivir, can modulate disease severity\textsuperscript{136}. Recent identification and characterization of broadly protective antibodies that recognize the active site of NA suggest that these antibodies could potentially be induced by vaccines\textsuperscript{137}. Antigenic drift and shift of NA is thought to occur independently of HA. As a result, N2 antibodies may have helped limit the severity of the H3N2 pandemic of 1968, in which the HA changed but the NA did not\textsuperscript{138}. Although the potential importance of NA as an influenza immunogen was recognized at the time of that pandemic\textsuperscript{139,140}, current seasonal influenza vaccine manufacturers are not required to measure the quantity or quality of NA in marketed products. Simply adding a known quantity of conformationally correct NA to current seasonal vaccines may improve efficacy and, potentially, breadth against drifted strains of influenza\textsuperscript{141,142}. Additional efforts, such as the creation of ‘consensus’ NA immunogens, are being tested in animal models and may hold promise for using NA as a component of a more universal vaccine\textsuperscript{143}.

\textit{Matrix protein 2 ectodomain}. Influenza A virus matrix protein 2 ectodomain (M2e) has been proposed as a universal vaccine antigen\textsuperscript{144,145}, but M2e presents multiple challenges. Although the M2 ion channel is essential for influenza virus budding and disassembly of the viral core, and, thus, is highly conserved, its surface-exposed amino terminal ectodomain is poorly immunogenic\textsuperscript{146}. If M2e is conjugated to various carriers or delivered as a virus-like particle, its immunogenicity improves\textsuperscript{147}. In fact, IgG-mediated protection from a broad range of
influenza virus strains has been demonstrated in animal models. However, this protection derives from Fc effector functions, and no robust immune correlate of protection has been established, which makes quantifying M2e-based immunity challenging and limits the measurement of vaccine efficacy to large field trials. A passively transferred human monoclonal antibody to M2e did decrease the viral load in a human influenza challenge model. The immune response of M2e can be improved with adjuvants, and, in a Phase I clinical trial, an M2e–flagellin fusion protein vaccine induced strong antibody responses at high dose, although the systemic reactivity profile was unacceptable. Given that M2e is a relatively small protein and viral escape mutants have been identified, it is more likely for an M2e-based vaccine to be used as an adjunct to HA-based vaccines to provide additional protective immunity, especially when there is a mismatch between the vaccine and circulating epidemic strains.

Nucleoprotein. Stimulation of CD4+ and/or CD8+ T cell responses, including recruiting intraepithelial tissue resident memory cells of the lung or T follicular helper cells crucial to germinal centre formation in the lymph node, may improve the durability, potency and breadth of influenza immunity. Both CD4+ and CD8+ T cell responses have been shown to be associated with heterosubtypic immunity against influenza. T cells have been implicated, both directly through CD8-mediated cytotoxicity and indirectly via CD4 help, in a breadth of protection in murine and non-human primate models of influenza infection. Although T cell-based immunity varies depending upon HLA type, and no absolute correlate of protection has yet been established, studies in humans have associated higher numbers of cross-reactive T cells with protection from influenza infection. NP is an internal protein conserved across influenza A strains that has been identified as a target of T cell immunity and studied in early phase clinical trials. An MVA-vectorized NP + M1 vaccine induced CD4+ and CD8+ T cell responses, detected by interferon-γ (IFNγ) enzyme-linked immunospot, across younger and older aged cohorts (Table 2). This vaccine also enhanced T cell and strain-specific antibody responses when used together with seasonal vaccines. In an influenza challenge, MVA NP + M1-vaccinated individuals had lower symptom scores than unvaccinated controls, although the number of individuals studied was small. As in the above-mentioned studies, viral vectored and nucleic acid-based vaccine platforms have been found to induce improved T cell responses over traditional inactivated influenza vaccines in animal models and in a human influenza virus challenge, and such alternative platforms may be required for a universal vaccine to effectively recruit T cells.

Vaccine adjuvants

Another way to improve influenza vaccines is to include adjuvants in vaccine formulations. Adjuvants are immunostimulatory agents that enhance the immunogenicity of the co-administered antigens. They can potentially provide other advantages, such as dose sparing, polarization of immune responses towards a more desirable response, acceleration of vaccine-induced immune response and increased immunogenicity in populations with poor immune responses, such as the elderly and patients who are immunosuppressed. Several adjuvants have been approved for use in influenza vaccines, including Alum, MF59, AS03 and AF03. The most widely used vaccine adjuvant, aluminium salt, showed little effect when used with H1N1 or H5N1 pandemic influenza vaccines. MF59, a squalene oil-in-water emulsion approved for influenza vaccines since 1997, increases antibody responses with both seasonal and pandemic subunit vaccines and has been shown to enhance protective efficacy against hospitalization associated with influenza. Similar to MF59, both AS03 and AF03 are oil-in-water adjuvants containing squalene with similar proposed modes of action. Both AS03 and AF03 have been approved for pandemic influenza vaccines. In general, these adjuvants are safe and well tolerated, and improve both the potency and breadth of humoral immune responses. Other adjuvants have been tested in animal models and clinical trials, including saponins, Toll-like receptor (TLR) agonists, polysaccharides and glycolipids. Saponins are amphiphilic glycosides commonly found in plants, and a newer generation of saponin-based adjuvant, Matrix-M, has advanced to a phase II trial and showed efficacy with an H7N9 virus-like particle vaccine.

TLR agonists improve vaccine efficacy and antitumour immunity by promoting innate inflammatory responses and inducing adaptive immunity. This class of adjuvants covers a very broad spectrum of pathogen-derived compounds, including lipopeptides, glycolipids, nucleotides, small-molecule inhibitors and bacterial-derived components, such as flagellin. TLR agonists, such as TLR4, TLR5, TLR7/8 and TLR9, have all been used with various influenza immunogens in animal studies and show varying degrees of increased efficacy in clinical trials. One major concern about these TLR ligands is the variation in the relevant receptors and the downstream signalling pathways and biodistribution in different species, which necessitates use of proper animal models or in vitro surrogates to establish the safety profile.

For the deployment of adjuvants in the next generation of influenza vaccines, careful consideration of efficacy in humans, as well as ease and consistency of manufacturing, will require careful consideration. More importantly, the safety of new adjuvants and vaccine risk–benefit considerations will need to be assessed. A safe and effective adjuvant has the potential to provide improved potency and breadth that might increase vaccine efficacy in normal and immune compromised subjects. Such an adjuvant could be a vital tool to provide either superior immune enhancement and/or dose sparing and, thus, help the efficacy and deployment of a universal influenza vaccine.

Clinical and regulatory considerations

Current influenza vaccines. The clinical development of universal influenza vaccines faces challenges not common to programmes for other pathogens. Although current vaccines are considered insufficient to address
the antigenic variation in seasonal influenza virus strains or the threat of pandemic strains, they have been in use for more than 70 years. A large enterprise and standardized practices have been established to support the $1.6 billion US market and estimated $4 billion global market\(^{187}\). The system involves semi-annual recommendations from the WHO (WHO: Influenza vaccine viruses and reagents), the Centers for Disease Control and Prevention (CDC) and collaborating centres for strain selection to include in vaccine formulations for the Northern and Southern Hemispheres. Vaccines are formulated and manufactured annually in a process that involves millions of embryonic eggs, genetic reassortment, amplification of vaccine viruses, and worldwide distribution\(^{188}\). Numerous organizations devote substantial resources to surveillance, evaluation and recommendations on vaccine efficacy, safety and clinical use. Although this cumbersome and elaborate system is entrenched, it produces only a few hundred million doses for the world’s 7 billion inhabitants, and vaccine efficacy is at best 60% in years when the vaccine viruses are well matched to circulating strains\(^{189}\). Nevertheless, the system is familiar, consistent, cost-effective and well understood, so displacing current practices is a significant hurdle for the development of new and potentially improved vaccine technologies. The availability of licensed vaccines also makes a placebo-controlled trial difficult to justify in countries, such as the United States, that recommend the current seasonal vaccine for wide use.

**Demonstrating clinical efficacy.** A major obstacle facing the clinical development of universal influenza vaccines is a well-established immune correlate of protection for influenza. Licensure of new seasonal vaccines is granted with evidence of efficacy obtained from past clinical trials with influenza illness as the primary end point, and approvals of annual supplements for new virus strains do not require additional clinical data specific for the new strain for inactivated and recombinant protein vaccines\(^{190}\).

Evaluating the efficacy of novel influenza vaccines may require giving the experimental vaccine in addition to conventional seasonal vaccine and determining whether efficacy is improved when circulating strains are mismatched with the seasonal vaccine. To demonstrate efficacy, clinical trials will likely be large and complicated, with potential immune interactions between products. Therefore, understanding the basis of influenza immunity and development of additional laboratory measurements as surrogates for vaccine efficacy are needed. If an accepted surrogate end point can be induced by the candidate universal influenza vaccine — determined by large-scale efficacy studies — and the protection is comparable to or superior to that induced by conventional vaccines, field trials could be designed to compare the candidate with licensed vaccines head-to-head. If there is no surrogate for efficacy, advanced development becomes more difficult.

Vaccine-induced immune responses, such as HAI antibody titres, are often evaluated and used as a surrogate to extrapolate vaccine effectiveness, especially in vulnerable populations not included in the efficacy trials, and in the case of a pandemic, licensure is granted based on HAI titres with a commitment to assess efficacy during the pandemic\(^{190-192}\). HAI was originally developed in the 1950s as a surrogate for neutralization because the assay was rapid and easier to perform\(^{193}\). However, HAI depends on blocking access to the sialic acid binding pocket on the HA head. In most cases, antibodies with HAI activity are highly strain-specific. When trying to develop vaccine platforms that induce broad protective efficacy, having an immune correlate that favours strain-specific immunity can be detrimental, especially when trying to displace established products.

Most vaccine design approaches for achieving immunity against future drifted seasonal and pandemic strains purposely avoid the induction of antibodies to the sialic acid binding pocket, so the use of HAI as a surrogate end point for achieving accelerated licensure is not an option. Therefore, advancing universal influenza vaccines will likely require expensive field efficacy studies and, eventually, the development of other surrogate end points. For example, antigens targeting the HA stem, designed to elicit antibodies with broad cross-subtype recognition, will not induce HAI\(^34\). They will potentially induce neutralizing activity or Fc-mediated antibody functions that could be monitored\(^{194}\). Neutralizing activity is likely to be an acceptable surrogate for protection, as HAI was originally developed as a surrogate for neutralization, which is the mechanistic correlate being assessed by HAI. Other mechanisms of neutralization beyond blocking receptor binding have also been recognized\(^{195-197}\). Therefore, although HAI is sufficient for strain-specific protection because it reflects neutralization through blocking receptor interaction, HAI is not required for protection, and so induction of broad neutralizing activity could be a better surrogate marker of immunity against diverse influenza strains. Another reason to focus on neutralizing activity instead of HAI is the continuous change in genetics and antigenicity of influenza viruses. For example, as H3N2 viruses evolve glycosylation patterns on HA, receptor binding or NA agglutination of red blood cells often changes, making it difficult to characterize these viruses with standard reagents and assays\(^{198}\). Recent advances in HA probes for flow cytometry, single-cell analysis, sequencing technology and bioinformatics have led to the identification of antibody lineages associated with HA-stem-targeted broad neutralization of influenza strains across subtypes, and in some cases across groups. This type of analysis and application to vaccine-induced immune responses creates the possibility of using molecular sequencing of immunoglobulin genes from sorted B cells as clinical trial end points\(^{24,105,198,199}\). Although the association of antibody sequences and clinical outcomes from infectious diseases has not been established, these biomarkers represent a potential path forward\(^{200}\).

Other approaches to universal influenza vaccines include the ectodomains of the M2 protein that depends on Fc-mediated antibody-dependent cellular cytotoxicity\(^{201}\). Alternatively, vector-based and live-attenuated virus approaches may involve T cell-mediated protection in addition to neutralizing antibodies\(^{202,203}\). However, to date, there has not been an accepted surrogate end point...
for vaccine efficacy based on an in vitro cell-mediated cytolysis activity, so for vaccines that do not achieve a serological end point of HAI or neutralization, it is more likely that demonstration of clinical efficacy will be needed for regulatory approval.

Human influenza challenge has been studied extensively in the past, and there are new efforts to extend the capacity for these studies. The original establishment of an HAI titre of 1:40 as a correlate of protection and a surrogate end point for vaccine protection was, in part, based on data from human challenge. FDA-approved influenza challenge viruses are available, and studies have been completed to define safe challenge doses and to establish criteria for quantifying clinical illness. As for HAI in the past, immune correlates using more modern reagents and assays can be assessed in experimentally infected humans, and human challenge can also be used to test efficacy of vaccines and passively administered antibody. A major limitation of the human influenza challenge model is that the infection, by intent, is largely restricted to the upper airway. Prevention of lower airway disease is one major objective for vaccine development, so vaccine efficacy cannot be directly assessed for the clinical end point of primary interest. In addition, the numbers and diversity of influenza viruses available for human challenge study are limited so it will be difficult to show vaccine efficacy against multiple viruses. In general, higher doses of virus are used for challenge than are seen in natural infection. Nevertheless, if vaccines or passively administered monoclonal antibodies can prevent or diminish upper airway disease, or show an effect on viral load in the human challenge model, this may facilitate regulatory approval and may contribute to the identification of alternative immunological correlates of protection.

Post-licensure considerations. Many recently licensed influenza vaccines have been granted accelerated approval based on safety and induction of serum HAI, which is considered a surrogate marker of protection. However, accelerated approval comes with substantial post-marketing contingencies that add to the time and cost of influenza vaccine development. It is likely that novel influenza vaccines, even those with evidence to support licensure, will have post-marketing requirements. The FDA was specifically charged with establishing a post-market risk identification and analysis system by the FDA Amendments Act of 2007, in part a response to the 2005 avian influenza H5N1 threat. The FDA, the CDC and academic investigators have been developing methods for active post-marketing observational collection of safety data that together comprise a pharmacovigilance toolkit. The elements of this include the Vaccine Safety Datalink (VSD), started in 1990 to collect information from electronic medical records; the FDA Sentinel initiative launched in 2008 and its Post-licensure Rapid Immunization Safety Monitoring (PRISM) programme activated in 2016, which integrates administrative and claims data from hospitals and insurance companies, and Medicaid and Medicare databases.

The Vaccine Adverse Event Reporting System (VAERS), started in 1990, is a system for passively collecting data from health care providers, manufacturers and the public. Although observational data are inherently biased, they can support data obtained from randomized controlled trials, especially in cases of accelerated approval as may be expected during a public health crisis like an influenza pandemic. For example, during the 2009 pandemic, accelerated licensure was granted to a high-dose trivalent influenza vaccine (independent of the H1N1 outbreak) for use in the elderly based on superior induction of HAI as a surrogate of efficacy. Part of the licensure agreement was for the manufacturer to carry out post-marketing efficacy studies. A 31,000-person randomized controlled trial subsequently showed that the high-dose influenza vaccine demonstrated clear superior efficacy relative to the standard-dose vaccine.

Using the Medicare database, an observational study design to control for bias in health-seeking behaviour and other factors provided supportive data that efficacy was achieved. Another way to use observational data to assess influenza vaccine effectiveness and avoid most bias is to use a ‘test-negative’ case-control trial design. Subjects with laboratory-proven influenza are assigned as cases and those who test negative are designated controls. The frequency of vaccination in each group can be used to accurately estimate vaccine efficacy, especially if factors like the method of diagnosis, vaccine type and influenza strain are specified.

Outlook

Despite moderate-to-low efficacy, cumbersome manufacturing processes and long lead times for annual strain reformulation, the current production system of seasonal influenza vaccines has been relatively unchanged over the past 40 years. Advances across the fields of structural biology, influenza virology and immunity have set the stage for major advances towards improved seasonal and universal influenza vaccines. The influenza vaccine field’s acceptance of these technological advances is only the first step towards worldwide practical implementation of next-generation vaccines. Meaningful and lasting advances in the influenza vaccine field are now achievable, but they depend upon leveraging expertise, communication and cooperation from stakeholders across many disciplines, from funding agencies to basic scientists, epidemiologists, regulators, manufacturers and the public.

Seasonal influenza vaccine production remains an enormous challenge for manufacturers as the vaccines must be produced and released 6 months after the WHO announces the vaccine strains for the following season in a given hemisphere. Currently, there are three different production technologies approved for influenza vaccines: egg-based, cell-based and recombinant proteins. The majority of the licensed vaccines are made using embryonic chicken eggs, and even though this production system has remained unchanged for decades, it is still the only method that can meet the current annual need of seasonal influenza vaccine for the global population. Five hundred million doses are generated annually but could potentially produce 1.5 billion seasonal and 6.4 billion pandemic doses. Vaccines produced from cell culture were first approved by the FDA in...
and a synthetic HA vaccine was subsequently approved in 2013 (ref.21). This recombinant protein-based approach allows a process that does not require virus propagation and can be run on a large scale once the appropriate infrastructure is in place. Together with the recent advances in high-cell density, perfusion continuous flow processing22, this approach opens the door to producing next-generation subunit protein vaccines and meeting the increasing demand for safe, affordable and effective influenza vaccines.

Published online 14 February 2020
57. Florack, N. et al. A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques. PLOS ONE 12, e0181738 (2017).
58. Karagingil, A. A., Kingstad-Bakke, B., Anderson, T. K., Goldberg, T. L. & Osorio, J. E. Broad protection against H5N2 and H7N1 viruses and demonstrates that stem-directed antibodies can be induced by vaccination.
59. Weil, C. J. et al. Induction of broadly neutralizing H1N1 influenza virus antibodies. Science 329, 1060–1064 (2010).

This study shows that a gene-based prime/protein boost approach increased the breadth of neutralizing antibodies. F. QUALIF. THE H5N2 AND H7N1 VIRUSES AND DEMONSTRATES THAT STEM-DIRECTED ANTIBODIES CAN BE INDUCED BY VACCINATION.

60. Ledgovnos, E. et al. DNA priming and influenza virus immunogen: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11, 916–924 (2011).

This study shows in two phase I studies that DNA priming followed by a monovalent inactivated vaccine boost improved the neutralizing antibody response, and demonstrates that HA stem-directed antibodies can be induced by vaccination in humans.

61. Atsmon, J. et al. Priming by a novel universal influenza vaccine (Multimeric-001)–a gateway for improving immune response in the elderly population. Vaccine 38, 5422–5429 (2020).

62. Santos, J. J. S. et al. Development of an alternative modified live influenza B virus vaccine. J. Virol. 91, 8252–8266 (2017).

63. Ducatez, M. F. et al. Low pathogenic avian influenza (H9N2) in chicken: evaluation of an ancestral H9-MVA virus Ankara and adenovirus vaccines expressing the hemagglutinin gene. Vaccine 35, 49–57 (2016).

64. Florek, N. W. et al. Modified vaccinia virus Ankara (MVA) vaccine: results from a double-blinded, randomized phase 1 clinical trial in healthy volunteers. Vaccine 32, 5041–5048 (2014).

65. Low, J. G. et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized phase 1 trial in US volunteer. Vaccine 32, 5049–5054 (2014).

66. Pilet, S. et al. A plant-derived quadrivalent virus-like particle vaccine induces cross-reactive antibody and T cell immunity in healthy adults. Clin. Immunol. 168, 72–87 (2016).

67. van Doorn, E. et al. The immunogenicity and safety of a 3-valent MVA-H5N1 vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: phase 1 clinical trial. Medicine 96, e6359 (2017).

68. van Doorn, E. et al. Evaluation of the immunogenicity and safety of a 3-valent MVA-H5N1 vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: phase 1 clinical trial. Medicine 96, e6359 (2017).

69. Lee, P. S. & Wilson, I. A. Structural characterization of an H1N1 influenza virus hemagglutinin stalk- specific immunogen that can be displayed on a chimeric newcastle disease virus vectored vaccine expressing conserved influenza A virus hemagglutinin stalk antigens. J. Virol. 89, 269–279 (2015).

70. Krammer, F. et al. H5N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin. Vaccine Immunol. 21, 1153–1165 (2014).

71. Ellebedy, A. H. et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl Acad. Sci. USA 111, 13133–13138 (2014).

72. Nachbagauer, R. et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies with low pathogenic avian influenza virus. J. Virol. 88, 13260–13268 (2014).

73. Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines 3, 40 (2018).

74. Sui, J. et al. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza antibodies. Clin. Infect. Dis. 52, 1003–1009 (2011).

75. Yassine, H. M. et al. Use of hemagglutinin stem probes demonstrate prevalence of broadly reactive group 1 HA antibodies in humans. Sero. Res. 88, 6262–6269 (2019).

76. Hai, R. et al. Influenza viruses expressing chimeric hemagglutinin: global analysis of epitopes derived from different subtypes. J. Virol. 86, 5774–5781 (2012).

77. Krammer, F. et al. H5 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340–2343 (2014).

78. Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccines elicit broadly protective stalk-specific antibodies. J. Virol. 89, 9–30 (2015).

79. Veld, R. D., T ang, M. & Lager, K. M. Protection of rhesus macaques. Vet. Rec. 143, S62–S67 (2019).

80. Krammer, F. et al. Universal influenza virus vaccines that targeted the conserved hemagglutinin stalk and conserved sites in the head domain. J. Virol. 85, 5526–5572 (2011).

81. Sun, W. et al. Development of influenza B universal vaccine candidates using the “mosaic” hemagglutinin approach. J. Virol. 87, 5035–5045 (2013).

82. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 26, 1065–1070 (2019).

This study reports on the rational designs of an HA stem immunogen that can be displayed on a self-assembling nanoparticle and shows that this vaccine induced stem-directed antibodies and protected against heterologous viral challenges in animal models.

83. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective monomeric immunogen. Science 349, 1301–1306 (2015).

84. Krammer, F. et al. Design of pan-subtype group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of...
broadly neutralizing antibody lineages. MBio 10, e02810-18 (2019).

121. National Institutes of Health. Influenza H4 ferritin vaccine, alone or in prime-boost regimens with an inactivated influenza A/Wyoming/3/62 (H1N1) vaccine in healthy adults. https://clinicaltrials.gov/ct2/show/NCT03186781? cond=03186782&term=03186782&rank=0-3186785 (2018).

122. Bangaru, S. et al. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nat. Commun. 9, 2669 (2018).

123. Kaneklo, M. et al. Mosaic nanoparticle display of influenza virus vaccines. Nat. Biotechnol. 385, 566–572 (2019).

124. Raymond, D. D. et al. Conserved epitope on influenza virus hemagglutinin head defined by a vaccine-induced antibody. Proc. Natl. Acad. Sci. USA 115, 168–173 (2018).

125. Bangaru, S. et al. A site of vulnerability on the influenza virus hemagglutinin head trimmer interface. Cell 177, 1156–1162.e18 (2019). This study describes a human monoclonal antibody that recognized a conserved site on the trimmer interface of the HA head. This antibody inhibited virus spread and protected mice against viral challenge, possibly by disrupting the HA trimmer interface.

126. Watanabe, A. et al. Antibodies to a conserved influenza head interface epitope protect by an IgG4 antibody with low avidity. Cell 172, 1134–1135.e16 (2018).

127. Memoli, M. J. et al. Evaluation of antihemagglutinin and anti-neuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. MBio 7, e00417-16 (2016).

128. Colman, P. M. Influenza virus neuraminidase: why does it matter? Lancet Infect. Dis. 16, 123–136 (2017).

129. Nernyck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157–1163 (1999).

130. Tennyson, C. B. et al. Mosaic hemagglutinin of a recombinant M2e-flagellin influenza (STF2.4xM2e) in healthy adults. Vaccine 29, 5145–5152 (2011).

131. Hulett, J. W. et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to theTLR5 ligand flagellin. Vaccine 26, 201–214 (2008).

132. Bonnet, S. et al. Porous nanoparticles with self-adjuvanting M2e fusion protein and recombinant hemagglutinin provide strong and broadly protective immunity against influenza virus infections. Front. Immunol. 3, 59 (2012).

133. El Bakkouri, K. et al. Universal vaccine based on ecdomain of matrix protein 2 of influenza A: FC receptor and neuraminidase correlate for effective immunogenicity protection. J. Immunol. 186, 1022–1031 (2011).

134. Ramos, E. L. et al. Efficacy and safety of treatment with an antineuraminidase monoclonal antibody in experimental human influenza. J. Infect. Dis. 211, 1058–1064 (2015).

135. Zharkova, D., Mozdziankzka, K., Feng, J., Zhang, M. & Gerhard, W. Influenza type influenza escape mutants emerge in vivo in the presence of antibodies to the ecdomain of matrix protein 2. J. Virol. 79, 6644–6654 (2005).

136. Morabito, K. M. et al. Memory inflation drives tissue-resident CD8+ T cell maintenance in the lung after intranasal vaccination with influenza virus. J. Infect. Dis. 198, 1861 (2018).

137. Koutsakos, M., Nguyen, T. H. O. & Kedzierska, K. With a little help from T follicular helper friends. Humoral immunity to influenza vaccination. J. Immunol. 202, 360–367 (2019).

138. Eichelberger, C. M., & Monto, A. S. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target. Influenza Vaccines: A comprehensive update, pp. 71–78 (2007).

139. Wain, H. et al. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic influenza A/H1N1 as well as H5N1 influenza viruses. J. Virol. 87, 9290–9300 (2013).

140. Wolbrough, T. J. et al. Vaccination with adjuvanted recombinant haemagglutinin Vaccine induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio 6, e02254-15 (2015).

141. Eichelberger, C. M. & Monto, A. S. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J. Infect. Dis. 219, 575–580 (2019).

142. Samson, M. et al. Characterization of drug-resistant influenza virus A/H1N1 and A/H3N2 variants selected in vitro with lanshinavim. Antivir. Immunother. 6, 539–549 (2007).

143. Eichelberger, C. M. & Monto, A. S. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J. Infect. Dis. 219, 575–580 (2019).

144. Samson, M. et al. Characterization of drug-resistant influenza virus A/H1N1 and A/H3N2 variants selected in vitro with lanshinavim. Antivir. Immunother. 6, 539–549 (2007).

145. Eichelberger, C. M. & Monto, A. S. Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection. J. Infect. Dis. 219, 575–580 (2019).

146. Samson, M. et al. Characterization of drug-resistant influenza virus A/H1N1 and A/H3N2 variants selected in vitro with lanshinavim. Antivir. Immunother. 6, 539–549 (2007).

147. Stadlbauer, D. et al. Broadly protective human antibodies that block the active site of influenza virus neuraminidase. Science 366, 499–504 (2019). This study isolates human monoclonal antibodies that block the active site of influenza virus neuraminidase.

148. Schuham, J. L. & Kilbourne, E. D. Induction of partial specific heterologous immunity in mice by a single infection with influenza virus. J. Bacteriol. 169, 1861–1867 (1980).

149. Deshusses, J. M. et al. A broad-spectrum human antibody specific for the conserved cross-reactive site on influenza hemagglutinin. Proc. Natl Acad. Sci. USA 98, 10028–10033 (2001).

150. Jetter, R. A., Barber, W. H. & Small, P. A. Jr. Heterotypic immunity to influenza and influenza vaccines in ferrets. Infect. Immun. 66, 1678–1686 (1998).

151. Clegg, C. H. et al. GLA-ALF, an emulsion-free vaccine adjuvant for pandemic influenza. J. Infect. Dis. 205, 2332–2335 (2012).

152. Desbies, L. A. et al. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-1β, and IFN-γ. J. Immunol. 189, 4091–4100 (2012).

153. Trenor, J. J. et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (STF2.4xHemagglutinin) in healthy adults aged over 50 years without a stable in-flu-water emulsion containing glycyrrhetinic acid (S + GLA) adjuvant. Vaccine 31, 5760–5765 (2013).

154. Desbies, L. A. et al. Squalene emulsion potentiates the adjuvant activity of the TLR4 agonist, GLA, via inflammatory caspases, IL-1β, and IFN-γ. J. Immunol. 189, 4091–4100 (2012).

155. Vincent, V. N. et al. A formulated TLR7 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines. Sci. Rep. 7, 46426 (2017).

156. Hartmann, G. et al. Deletion of a CpG phosphorothioate oligodeoxynucleotide for activating primary immune responses in vivo and in vivo. J. Immunol. 161, 1617–1620 (1998).

157. Klinman, D. M., Yi, A. K., Beaugeac, S. L., Conover, J. & Krieg, A. M. CpG motifs present in bacteria DNA rapidly induce lymphocytes expressing IL-12 and interferon γ. Proc. Natl Acad. Sci. USA 93, 2878–2883 (1996).

158. Krug, A. et al. CpG-oligodeoxynucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells. J. Immunol. 170, 5468–5477 (2003).

159. Yang, F. et al. Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus. J. Virol. 84, 8569–8588 (2010).
